Letters

COMMENT & RESPONSE

Risk Index and Thrombolytic Treatment in Acute Ischemic Stroke

To the Editor In the article by Ovbiagele et al1 published in JAMA Neurology—which tested the hypothesis that patients with stroke with a positive SPAN-100 index (the sum of a patient’s age plus National Institutes of Health Stroke Scale of 100 or greater) selected from the Virtual International Stroke Trials Archive (VISTA) database might benefit from thrombolysis—the authors concluded that such SPAN-100-positive patients “should probably not be denied thrombolysis treatment on the basis of such a profile alone.” Likewise they conclude that “[t]he VISTA database does not sanction reanalysis of any trial data that will test treatment effects....” However, our observational study did not set out to reanalyze the efficacy of a given thrombolytic agent, but rather to assess the impact of thrombolytic agents administered as part of routine clinical practice in acute stroke trials of neuroprotective agents. We should also emphasize that our study should only be viewed as hypothesis generating. Indeed, the observation that older patients with more severe strokes gain more from intravenous thrombolysis treatment on an absolute scale simply leads to the conclusion that this group of patients may not necessarily have to be denied treatment just on the basis of age or stroke severity and that more study of intravenous thrombolysis use in elderly patients with severe strokes is needed. Finally, the lack of efficacy of intravenous thrombolysis in the SPAN-100-negative patients might have been because the nonrandomized assignment led to a residual treatment selection bias.

Bruce Ovbiagele, MD, MSc, MAS
Gustavo Saposnik, MD, MSc, FRCP

In Reply We thank Dr Little for his interest in our article.1 Dr Little is correct in that “[t]he VISTA database does not sanction reanalysis of any trial data that will test treatment effects....” However, our observational study did not set out to reanalyze the efficacy of a given thrombolytic agent, but rather to assess the impact of thrombolytic agents administered as part of routine clinical practice in acute stroke trials of neuroprotective agents. We should also emphasize that our study should only be viewed as hypothesis generating. Indeed, the observation that older patients with more severe strokes gain more from intravenous thrombolysis treatment on an absolute scale simply leads to the conclusion that this group of patients may not necessarily have to be denied treatment just on the basis of age or stroke severity and that more study of intravenous thrombolysis use in elderly patients with severe strokes is needed. Finally, the lack of efficacy of intravenous thrombolysis in the SPAN-100-negative patients might have been because the nonrandomized assignment led to a residual treatment selection bias.

Bruce Ovbiagele, MD, MSc, MAS
Gustavo Saposnik, MD, MSc, FRCP

Treating Idiopathic Intracranial Hypertension

To the Editor In their article regarding the idiopathic Intracranial Hypertension (IIH) Treatment Trial (IIHTT), Wall and colleagues stated that “there are no properly designed and executed clinical trials to guide therapy.”1 They quoted Lueck and McIlwaine2 who correctly concluded a dearth of properly designed clinical trials in IIH at the time of their publication. In using this article, Wall et al1 did not consider a number of important published studies in the intervening 5 years since this Cochrane review2 was updated in 2008.

In 2011, Ball et al3 prospectively evaluated acetazolamide use in mild IIH, similar to the IIHTT. Fifty patients were recruited and randomized to receive acetazolamide or no acetazolamide. Symptoms, body weight, visual function, and quality-of-life measures were recorded. Most showed improvement, with 44% judged to be in remission at trial end. Mean weight loss was 6.2 kg (5.8%) and 3.3 kg (3.5%) in the treatment arm and control arm, respectively. Difficulties with recruitment and poor compliance with acetazolamide were highlighted. Acetazolamide was discontinued in 48%.
Sinclair et al\textsuperscript{a} reported a prospective cohort study in 2010 in patients with chronic IIH. Here, a low-energy diet for 3 months reduced intracranial pressure from baseline and was maintained 3 months after diet cessation. They also demonstrated improved symptoms and a reduction in papilledema, as objectively measured with optical coherence tomography and ultrasonography.

The major complication in IIH is severe and permanent visual loss, which fortunately is rare. The IIHTT considered that the rate of bilateral blindness in IIH is 10%. Best et al\textsuperscript{b} published a British Ophthalmic Surveillance Unit study finding only 0.6% to 2% of new IIH cases would be expected to be severely sight impaired per year. Most patients with IIH have relatively mild visual loss; in many, there are issues in quantifying the visual deficit where disc swelling can mask the visual field and where there are nonorganic exaggerated visual field findings. In our experience, those who have severe visual loss present, or are not identified early enough, with fulminate disease.

The interest of this large IIH cohort really lies in whether the IIHTT can characterize the disease further than is currently known, in particular, whether the researchers are able to postulate disease mechanisms and what to consider targeting for treatment. We eagerly await the results of the IIHTT substudies investigating vitamin A metabolism and the genetic markers.

Susan P. Mollan, MB, cHB, FRCOphth
Michael A. Burdon, MB, cHB, MRCP, FRCOphth
Alex J. Sinclair, MB, cHB, MRCP, PhD

Author Affiliations: Neurotrauma and Neurodegeneration, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, The Medical School, University of Birmingham, Birmingham, England (Mollan, Sinclair); Birmingham Neuro-Ophthalmology Unit, Ophthalmology Department, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Birmingham, England (Mollan, Burdon); Neurology Department, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Birmingham, England (Sinclair).

Corresponding Author: Susan P. Mollan, MB, cHB, FRCOphth, University Hospitals Birmingham, Neuro-Ophthalmology, Queen Elizabeth Hospital, Birmingham, West Midlands B15 2WB, England (soozmollan@doctors.org.uk).

Conflict of Interest Disclosures: None reported.

Funding/Support: Dr Sinclair is funded by a National Institute for Health Research Clinician Scientist Fellowship (NIHR-CS-011-028) and the Medical Research Council, United Kingdom (MR/K015184/1).

Role of the Funder/Sponsor: The funders had no role in the preparation, review, or approval of the manuscript, and the decision to submit the manuscript for publication.


In Reply We thank Mollan and colleagues for their interest in our treatment trial.\textsuperscript{1} We were aware of the pilot study by Ball and colleagues.\textsuperscript{2} We stated that treatment of idiopathic intracranial hypertension is based on anecdotal and uncontrolled data because there were no properly designed and executed clinical trials to guide therapy prior to ours. We did not cite the Ball et al\textsuperscript{2} pilot work because its results were inconclusive with respect to efficacy owing to the small sample size and consequent low power. Indeed, Ball et al stated in the article that “[t]his pilot study was not powered to detect a treatment effect.”\textsuperscript{2} Also, 12 of 25 patients in the acetazolamide group stopped taking the medication during the study, a discontinuation rate of nearly 50%. Dosing schedules for acetazolamide were at the discretion of the supervising clinician and did not reach more than 1500 mg per day. Twenty percent of the participants in the control group were eventually given acetazolamide. No conclusions could be drawn from their trial because of these study design issues.

We are also well aware of the study by Sinclair et al\textsuperscript{a} that suggested that weight loss was associated with a decrease in cerebrospinal fluid pressure. While space limitations precluded us from discussing it in our article,\textsuperscript{1} the results have a prominent place in the slide set we distributed to our investigators. The outcome of the Idiopathic Intracranial Hypertension Treatment Trial is now published.\textsuperscript{4} Our diet-plus-acetazolamide group had twice the amount of weight loss as did the diet-plus-placebo group, and a mediation analysis showed that the effect of acetazolamide on improving vision was independent of its effect on weight loss.

We thank Mollan and colleagues for pointing out the Best et al study.\textsuperscript{3} As Best et al\textsuperscript{3} acknowledged, with studies like theirs, underreporting is a concern so the true incidence is not known. The figure of 10%, also cited in the Ball et al study,\textsuperscript{2} comes from data from academic centers and is prone to selection bias. Best et al\textsuperscript{3} reported a yearly incidence and we quoted the true lifetime incidence. Needless to say, it is difficult to determine the true lifetime incidence of blindness in idiopathic intracranial hypertension.

Michael Wall, MD
Michael P. McDermott, PhD
Karl D. Kieburtz, MD, MPH
Mark J. Kupersmith, MD

Author Affiliations: Department of Neurology, University of Iowa, Iowa City (Wall); School of Medicine and Dentistry, University of Rochester, Rochester, New York (McDermott); Department of Neurology, University of Rochester Medical Center, Rochester, New York (Kieburtz); Division of Neuro-Ophthalmology, Roosevelt Hospital, New York, New York (Kupersmith).

Corresponding Author: Michael Wall, MD, Department of Neurology, University of Iowa, 200 Hawkins Dr, Ste 2149, Iowa City, IA 52242-1009 (michael-wall@uiowa.edu).

Conflict of Interest Disclosures: None reported.


CORRECTION
Incorrect Information in Tables and Figure Caption: In the Original Investigation titled “Genome-Wide Analysis of the Heritability of Amyotrophic Lateral Sclerosis,” published in the September 2014 issue (2014;71[9]:1123-1133. doi:10.1001/jamaneurol.2014.1184), incorrect information appeared in Tables 2 and 4 and in the caption to Figure 1. On page 1125, the numbers 16 566 574, 16 505 937, and 17 070 203 in the last column of Table 2 should be replaced by the numbers 4 847 835, 4 835 273, and 4 894 283, respectively. In the first sentence of the caption to Figure 1 on page 1127, “study size” should be replaced by “effect size.” On page 1128, the first part of Table 4 should read “Genotyped Data,” and the second part should read “Imputed Data.” This article was corrected online.

Call for Papers

*JAMA Neurology* is announcing a new journal feature, Clinical Challenge, which will be published quarterly, under the section editorship of Lawrence S. Honig, MD, PhD. The goal of this feature is to present short clinical problems to challenge readers to arrive at the correct diagnosis from a small data set, including images. Readers will see a short clinical synopsis and relevant images or laboratory information allowing them to exercise their diagnostic skills. Actual correct diagnosis and a brief discussion will be available on the following page of the journal or on the Discussion tab online. The overall format of this feature will be like that of the current highly successful feature What is Your Diagnosis?, which has been running since January 2011, available on the web quarterly, only online. Clinical Challenge will be the successor to this feature but will be an integral journal section, viewable interactively online and in the print version of the journal, and indexed like other articles. *JAMA Neurology* welcomes submissions to this feature, for which any submission should include a maximum of up to 3 authors. The format must include (1) a paragraph introducing and describing the clinical case (no more than 250 words); (2) 1 to 3 figures including imaging, electrophysiological, and/or other laboratory data; (3) 4 multiple-choice potential answers for diagnosis; and (4) a paragraph of discussion (no more than 600 words) disclosing the actual diagnosis (confirmed by conclusive tissue pathology, genetic, or other test), and including up to 10 references. We invite submissions through the standard *JAMA Neurology* submissions process.